Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is It Too Late to Buy Vaxart Stock?

TheMotleyFool

0 0

On June 11, Vaxart (NASDAQ: VXRT) stock skyrocketed 22% after Piper Sandler analyst Yasmeen Rahimi initiated coverage of the company with a price target of $18. That represents an upside of 151% from that day's open.

In setting the price target, the analyst cited the validation of the company's novel adenoviral platform, Ad5, in 200 clinical studies. Vaxart is using the technology to develop a novel, pill-based oral coronavirus vaccine candidate. According to the analyst, five clinical datasets (not just for the coronavirus indication) involving 580 healthy volunteers support the safety and efficacy of Ad5, leading to "potent" and "safe" drug candidates with a "high chance of success." Is now the time to buy Vaxart?

Image source: Getty Images.

Source Fool.com

Like: 0

VXRT

Share